Dermata
Dermata
Dermata Therapeutics

We have partnered with Dermata Therapeutics, LLC , a private specialty pharmaceutical company developing innovative prescription drugs for dermatological conditions. We have out-Licensed SIG-990 (aka DMT200/DMT210) to Dermata Therapeutics for the topical treatment of rosacea. SIG-990 (aka DMT200/DMT210) is a novel, first-in-class anti-inflammatory compound which has the potential to both reduce erythema and decrease the papules and pustules associated with the disease. The Investigational New Drug (IND) application for SIG-990 (aka DMT200/DMT210) has been cleared by the U.S. Food and Drug Administration (FDA) and SIG-990 (aka DMT200/DMT210) is thus ready to be evaluated in subjects. Dermata has obtained an exclusive worldwide license to SIG-990 (aka DMT200/DMT210) and is responsible for the clinical development of the product. Dermalogix will receive milestone payments and royalties on revenues of the product.